Transfersomes in Advanced Drug Delivery:
A Comprehensive Review of Design, Mechanism, and Clinical Applications
Junaid S Shaikh1*, Bhavesh Akbari2
1Research Scholar, School of Pharmacy, P.P. Savani University, Kosamba, Surat, Gujrat.
2Principal and Professor, School of Pharmacy, P.P. Savani University, Kosamba, Surat, Gujrat.
*Corresponding Author E-mail: skjunaid.pharm@gmail.com
ABSTRACT:
The advancement of transdermal drug delivery systems (TDDS) marks a significant shift in pharmaceutical technology, offering non-invasive, sustained, and targeted therapy. Transfersomes—highly deformable, lipid-based vesicles—have revolutionized this domain by overcoming the skin’s natural barrier, the stratum corneum. Composed of phospholipids and edge activators, these vesicles exhibit exceptional flexibility, allowing efficient penetration into deeper skin layers and enabling both local and systemic drug delivery. Transfersomes are capable of encapsulating hydrophilic and lipophilic drugs, improving bioavailability, reducing dosing frequency, and minimizing systemic side effects. They are especially beneficial in managing skin-related diseases such as cancer, psoriasis, and chronic wounds. Despite some formulation and stability challenges, their adaptability, safety, and proven effectiveness in both preclinical and clinical studies make them a powerful tool in modern drug delivery. This review explores the mechanisms, formulation techniques, influencing factors, and broad applications of transfersomes, underlining their transformative role in future therapeutics.
KEYWORDS: Transfersomes, Transdermal Drug Delivery, Skin Penetration, Controlled Drug Release, Bioavailability Enhancement.
The transdermal drug delivery system (TDDS) has emerged as a crucial advancement in pharmaceutical sciences, offering a non-invasive and patient-friendly alternative to traditional routes of drug administration. By bypassing the gastrointestinal tract and hepatic first-pass metabolism, TDDS enhances bioavailability and ensures more consistent plasma drug levels, thereby improving therapeutic outcomes1.
This mode of delivery reduces the frequency of dosing and minimizes side effects commonly associated with oral and parenteral therapies, making it especially beneficial for chronic disease management. One of the key advantages of TDDS lies in its ability to deliver both hydrophilic and lipophilic drugs in a controlled and sustained manner. The system also facilitates localized treatment while reducing systemic exposure, which is particularly useful for dermatological conditions2. Moreover, recent innovations such as transfersomes—ultra-deformable lipid vesicles—have revolutionized TDDS by overcoming the barrier properties of the stratum corneum. These carriers can efficiently penetrate the skin’s outer layer without causing damage, thus enabling deeper tissue targeting and enhanced drug efficacy3,4.
1.1. Transfersomes:
Advancements in drug delivery systems have significantly reshaped therapeutic approaches, with nanocarrier-based technologies offering enhanced drug bioavailability, targeted action, and reduced systemic toxicity. Among these, Transfersomes—ultra-deformable, lipid-based vesicular systems—have emerged as a promising innovation for the non-invasive delivery of a wide array of bioactives across biological barriers, particularly the skin and mucosa.1,3.
Transfersomes are specialized elastic vesicles composed primarily of phospholipids and an edge activator, such as surfactants, which impart high deformability to the vesicle membrane. This structural adaptability enables them to traverse through narrow pores and intercellular spaces significantly smaller than their own diameter, making them ideal candidates for transdermal and topical drug delivery1,4. Unlike conventional liposomes, which face limitations in penetrating the stratum corneum, transfersomes can squeeze through the skin’s lipid matrix without causing damage, thus ensuring deeper and more effective drug permeation3.
Recent research has extended the applicability of transfersomes beyond transdermal systems to the delivery of complex therapeutics such as anti-inflammatory agents, antifungals, peptides, vaccines, and polyphenol-rich formulations2. Their ability to encapsulate both hydrophilic and lipophilic drugs, combined with their improved skin penetration profile, has led to increased interest in their clinical development and patenting4.
Fig.No.1. Structure of transferosome
1.1.1 Advantages of Transfersomes:
a) Enhanced Skin Penetration:
Transfersomes are ultra-deformable and capable of passing through narrow intercellular spaces in the stratum corneum, leading to superior skin permeation.5
b) Improved Drug Bioavailability:
Their ability to cross biological membranes without degradation improves systemic and local bioavailability of encapsulated drugs.6.
c) Sustained and Controlled Drug Release:
Transfersomes provide a prolonged release of drugs, minimizing dosing frequency and enhancing patient compliance.7.
d) Non-Invasive and Painless Delivery:
As a topical/transdermal system, transfersomes offer a non-invasive alternative to injections, suitable for chronic therapies8.
e) Versatility in Drug Loading:
Both hydrophilic and lipophilic drugs can be efficiently encapsulated and delivered using transfersomes.9.
f) Targeted Delivery with Reduced Side Effects:
Transfersomes can localize drug action at the desired site, reducing systemic toxicity, especially in dermatological and cancer treatments10.
g) Biocompatibility and Safety:
Made primarily of phospholipids and safe surfactants, transfersomes are generally non-toxic and skin-compatible.11
1.1.2. Disadvantages of Transfersomes:
a) Formulation Complexity:
Requires precise optimization of phospholipids, edge activators, and process parameters, which may complicate scale-up12.
b) Stability Issues:
Transfersomes may exhibit limited physical and chemical stability during long-term storage due to vesicle aggregation or oxidation of lipids13.
c) Short Shelf Life:
Compared to conventional dosage forms, transfersomes are more prone to degradation and require cold-chain storage.14
d) Skin Irritation Potential:
Surfactants used as edge activators can sometimes cause mild skin irritation or sensitization, depending on concentration.5.
1.1.3. Limitations of Transfersomes:
a) Inadequate Penetration in Diseased or Damaged Skin
Transfersomes may face difficulty in uniform penetration when the skin barrier is compromised or altered, such as in scarred tissue15.
b) Drug Leakage and Vesicle Fusion
Instability in vesicle structure may lead to premature drug leakage, reducing the therapeutic efficacy.16
c) Manufacturing and Regulatory Challenges
The need for stringent quality control, scalability, and regulatory approval can hinder commercialization.17
2. Mechanism of Action of Transfersomes:
Transfersomes are ultra-deformable, phospholipid-based vesicular systems specifically engineered to overcome the barrier properties of the stratum corneum and deliver drugs effectively through the skin. Their mechanism of action is fundamentally rooted in their unique bilayer architecture, which includes a combination of phospholipids and edge activators (such as surfactants), granting them exceptional flexibility and deformability. This ultra-elastic nature allows transfersomes to traverse narrow intercellular spaces in the skin, far smaller than their own size, without causing structural damage to the skin layers12,18.
Upon topical or transdermal application, transfersomes are drawn into deeper skin layers by the natural transdermal hydration gradient. As water is lost through the skin, it creates osmotic pressure that acts as a driving force for the vesicles, propelling them through the stratum corneum into the viable epidermis and dermis5. This penetration is further enhanced by the edge activators, which temporarily disrupt the lipid packing of skin layers, allowing the vesicles to deform and squeeze through tight junctions16. Once inside the deeper skin layers or systemic circulation, transfersomes gradually release their drug payload, ensuring a sustained and controlled release profile7,9.
The enhanced permeation property of transfersomes significantly contributes to improved drug bioavailability, especially for molecules that are poorly absorbed via conventional routes. Studies have shown that transfersomal formulations of drugs such as methylphenidate6, clindamycin13, and tacrolimus5 achieve markedly higher therapeutic levels compared to traditional gels or creams. In particular, the use of biocompatible permeation enhancers, such as hyaluronic acid or chitosan, further amplifies skin penetration while maintaining the skin’s integrity11, 17.
Moreover, transfersomes are capable of targeted and localized delivery, as demonstrated in treatments for cutaneous leishmaniasis12, dermatitis5, and hypertrophic scars 15. These properties not only enhance therapeutic efficacy but also reduce systemic exposure and associated side effects. Additionally, by tailoring vesicle size, surface charge, and composition, transfersomes can be optimized for disease-specific targeting, thereby expanding their clinical relevance across dermatological, neurological, and oncological applications10.
In conclusion, the mechanism of action of transfersomes involves a combination of physical flexibility, biochemical compatibility, and osmotic responsiveness, leading to enhanced permeation, sustained drug release, and improved bioavailability. These properties make transfersomes a cutting-edge platform for transdermal and topical drug delivery, holding immense promise in next-generation therapeutics.
Fig.No.2. Mechanism of transferosomes into skin penetration
3. COMPOSITION:
Table No.1- Common ingredients to make transferosomes with role
|
Sr. No. |
Component |
Example |
Role
|
|
1. |
Phospholipids |
Soya phosphatidylcholine (SPC), egg phosphatidylcholine, dipalmitoyl PC |
Form the lipid bilayer; provide vesicle structure and integrity |
|
2. |
Edge Activators (Surfactants) |
Sodium cholate, sodium deoxycholate, Tween 80, Span 80, Span 60 |
Increase bilayer flexibility and deformability for skin penetration |
|
3. |
Solvents |
Ethanol, methanol |
Dissolve lipids and edge activators during film‑formation step |
|
4. |
Hydration / Buffer Medium |
Phosphate‑buffered saline (pH 6.4–6.5) |
Hydrates lipid film to form vesicles and maintain physiological pH |
|
5. |
Optional Additives |
Dyes (e.g. Rhodamine‑123, Nile red); cholesterol; propylene glycol |
Used for imaging, stability modulation or enhanced skin interaction |
4. Methods of Preparation of Transferosomes:
The preparation method of transferosomes significantly influences their physicochemical properties, including vesicle size, encapsulation efficiency, deformability, and stability. Multiple techniques have been developed and optimized over time to achieve uniform, scalable, and reproducible transferosomal formulations. Below are the detailed methodologies commonly employed in the preparation of transferosomes:
1. Thin-Film Hydration Method19
This is one of the most widely adopted and traditional techniques for preparing transferosomes due to its simplicity and effectiveness in forming multilamellar vesicles. In this method, lipids such as phosphatidylcholine and edge activators (e.g., sodium deoxycholate, Tween 80) are first dissolved in a volatile organic solvent mixture, commonly chloroform: methanol (2:1 v/v). This mixture is then transferred to a round-bottom flask and subjected to rotary evaporation under reduced pressure to remove the solvent, leaving behind a thin and uniform lipid film on the inner surface of the flask. This step is typically conducted at a temperature slightly above the lipid’s phase transition temperature (Tc) to ensure proper film formation. Subsequently, the lipid film is hydrated using a pre-warmed aqueous phase, usually phosphate-buffered saline (PBS), resulting in the formation of multilamellar vesicles. These vesicles are then downsized using probe sonication, bath sonication, or membrane extrusion techniques to obtain nanosized, unilamellar or oligolamellar vesicles with improved deformability and homogeneity.
2. Modified Hand-Shaking and Vortex-Sonication Method:20
This method is a simple variation of the conventional thin-film technique and is particularly useful for laboratory-scale and pilot experimental setups. In this method, the lipid and surfactant mixture is allowed to dry while being gently hand-shaken in a container, forming a thin lipid film without the use of advanced evaporators. Following film formation, a measured amount of buffer solution is added, and the mixture is subjected to vortexing to promote initial hydration. To further reduce the vesicle size and ensure proper dispersion, the hydrated mixture is then exposed to ultrasonic treatment using a sonicator. The key advantage of this method lies in its ease of operation and minimal equipment requirement, making it suitable for exploratory studies or quick screening of formulation variables.
3. Suspension Homogenization with Freeze–Thaw Cycles:21
This method involves preparing a lipid–surfactant dispersion by dissolving the components in a mixture of ethanol and water. Once the primary dispersion is formed, it is subjected to repeated cycles of freezing (typically at −80 °C) and thawing (at room or physiological temperature). These cycles facilitate the fusion and rearrangement of vesicle bilayers, enhancing the entrapment of hydrophilic and hydrophobic drugs while also reducing the chances of drug leakage. The freeze–thaw process helps improve the physical stability of the vesicles and is particularly effective for encapsulating biologically sensitive molecules such as proteins and peptides.
4. Ethanol Injection Method:22
The ethanol injection method is a straightforward and efficient approach for producing transferosomes with relatively narrow size distribution. In this technique, phospholipids and surfactants are dissolved in ethanol, which serves as a lipid-carrying phase. This organic phase is then slowly injected, often dropwise or through a syringe pump, into a preheated aqueous solution (commonly PBS or distilled water). Due to the diffusion of ethanol into the aqueous medium, spontaneous vesicle formation occurs. The system is kept under stirring during injection to ensure uniform distribution. After complete injection, ethanol is removed under vacuum using rotary evaporation or other suitable means. This method produces unilamellar vesicles with good size control and is advantageous due to its simplicity and reproducibility.
5. Reverse-Phase Evaporation Method:23
This technique is particularly beneficial for formulating transferosomes with high aqueous core entrapment, making it suitable for hydrophilic drug delivery. The process begins by emulsifying the lipid and drug components in a two-phase system composed of an organic solvent (e.g., diethyl ether, isopropyl ether) and an aqueous phase (buffer). Upon the application of sonication or homogenization, a stable water-in-oil (W/O) emulsion is formed. This emulsion is then subjected to evaporation under vacuum, removing the organic phase gradually and resulting in the collapse of the emulsion droplets into lipid bilayer vesicles. This method yields vesicles with large internal aqueous volumes and high encapsulation efficiency for water-soluble molecules.
6. Freeze–Thaw Plus Extrusion Method:24
This combined approach utilizes the advantages of both freeze–thaw cycling and membrane extrusion for the preparation of highly stable and size-controlled transferosomes. Initially, hydrated vesicle dispersions are subjected to multiple cycles of freezing (typically at –80 °C) and thawing (at room temperature), which promotes lipid bilayer fusion, reduces drug leakage, and enhances entrapment efficiency. After this, the vesicle suspension is passed through polycarbonate membranes of defined pore sizes using an extruder to achieve uniform particle size and a narrow PDI. This technique is particularly beneficial when the goal is to obtain highly monodisperse vesicle populations suitable for intravenous or transdermal applications.
7. Supercritical CO₂ (SCF) and Flow-Reactor Based Continuous Techniques:25
Emerging technologies such as supercritical fluid-based methods and microfluidic flow-reactor systems are gaining prominence due to their scalability and environmentally friendly nature. In the SCF approach, lipids and drug substances are processed under supercritical CO₂ conditions, which act as a solvent and anti-solvent system depending on the setup. This method eliminates the need for harmful organic solvents and allows the production of solvent-free vesicles. Similarly, flow-reactor-based systems use microfluidic mixing under controlled flow rates and pressure to generate highly uniform and reproducible transferosomes. These advanced methods are especially promising for large-scale industrial production due to their continuous operation, precise control over process parameters, and potential for automation.
8. Special Methods:
a. Iontophoresis-Based Transferosomes:26
In this innovative approach, transferosomes are first prepared using a thin-film hydration method involving surfactants such as sodium cholate or sodium deoxycholate with soya phosphatidylcholine (SPC). The formulation is then optimized using Design of Experiments (DoE) to refine critical parameters such as surfactant concentration, drug loading, and vesicle size. The unique aspect of this method is the application of the prepared transferosomal formulation via iontophoresis—a technique that uses mild electrical currents to enhance skin penetration. Ex vivo models, such as porcine nipple skin, are often employed to evaluate the efficiency of this delivery system. This method is particularly effective for enhancing drug delivery through thicker skin regions or specific dermal layers.
b. Asiatic Acid Transfersomal Gel Method:27
This method is tailored for the topical delivery of bioactives such as asiatic acid. The transferosomes are initially prepared using the thin-film hydration technique by combining various surfactants (e.g., Tween 80, Span 80, or sodium deoxycholate) with soybean lecithin to optimize vesicle properties. After hydration, the vesicles are further refined using high-pressure homogenization to reduce particle size and improve stability. The final transferosomal suspension is then incorporated into a hydrogel base to facilitate ease of application and prolonged retention on the skin. This combination results in a highly bioavailable topical formulation with enhanced therapeutic efficacy.
5. Factors Affecting Transferosome:
1. Composition and Type of Edge Activator:28
The choice and concentration of surfactants (e.g., sodium deoxycholate, Tween 80, sodium lauryl sulfate) significantly influence vesicle deformability, drug encapsulation efficiency, and penetration through the stratum corneum. For instance, studies optimizing itraconazole transferosomes found that SDC and SLS yielded high encapsulation efficiency (89–98 %) with sizes ranging from ~133 to 384 nm and low PDI, directly correlating with type and concentration of edge activator.
2. Particle Size, PDI, and Zeta Potential:29
Smaller particle sizes (e.g., ~65–152 nm) and narrow PDI (< 0.5) enhance homogeneity and stability, while a moderately negative zeta potential (e.g., –13 mV to –36 mV) prevents aggregation and promotes longer shelf life. A Box–Behnken optimized proanthocyanidin-loaded transferosome formulation showed ~65nm and zeta potential of –13mV, while ascorbic acid transferosome gels had ~152nm size, PDI ~0.571, and ZP ~–36.5mV, improving physical stability of the vesicles.
3. Lipid-to‑Drug Ratio and Entrapment Efficiency:30
Higher lipid content relative to drug loading typically boosts entrapment efficiency. For example, dual‑drug (berberine HCl and diacerein) transferosomes achieved high loading efficiencies when optimized via Box–Behnken design and adjusting lipid proportions. Similarly, studies with lidocaine formulations adjusting lipid and surfactant ratios using factorial designs achieved EE > 90 % and sustained release up to 6hours.
4. Preparation Method and Experimental Design:29,31
Using systematic design-of‑experiments approaches (e.g., Box–Behnken, D‑optimal designs) allows fine‑tuning of factors such as Carbopol or propylene glycol levels, lipid and surfactant ratios, sonication time, and hydration cycles. This enhances reproducibility, vesicle uniformity, and performance.
5. Stability Under Storage Conditions:28
Stability testing—including thermal cycling and storage at 5°C—reveals that formulations maintaining negative zeta potentials (~–15 to –36mV) and low PDI remain physically stable (minimal aggregation) over weeks. Recombinant human EGF‑loaded transferosomes remained stable for at least one month at 5 °C (particle size ~233nm, ZP –15.46 mV).
6. Skin Permeation and Release Profile:29
Transferosomes with optimized deformability and composition deliver higher transdermal flux versus conventional vesicles. For instance, proanthocyanidin gels showed Jss ≈ 0.123mg/cm²/h, significantly higher than non-deformable formulations. Release kinetics also depend on surfactant-mediated membrane ripple formation, enhancing fusion and drug diffusion into deeper layers.
7.Hydration Medium and pH of Hydration Buffer:30
The pH and ionic strength of the hydration buffer can significantly influence vesicle formation and drug solubilization. For example, the use of citrate buffer (pH 5.5) versus phosphate buffer (pH 7.4) showed altered drug entrapment and release profiles for hydrophilic compounds in transferosomes. Lower pH conditions favored vesicle elasticity and improved skin penetration.
8. Use of Penetration Enhancers and Co-Surfactants:31
Co-administration of natural penetration enhancers like terpenes (e.g., menthol, limonene) and co-surfactants such as transcutol-P has shown synergistic effects in disrupting lipid bilayers and improving transferosomal flux. These agents reduce vesicle rigidity and promote intercellular delivery.
5.1. Biological and Pharmacotechnical Factors:
1. Skin Physiology and Barrier Integrity:32
The effectiveness of transferosomes largely depends on the condition and structural integrity of the skin barrier. Variations in the stratum corneum thickness, hydration levels, and lipid composition influence vesicle penetration. Damaged or inflamed skin exhibits altered lipid organization and higher permeability, which can enhance or hinder drug diffusion depending on the molecule's characteristics. Additionally, areas with thinner skin (e.g., eyelids) offer greater permeation potential than thicker regions (e.g., palms).
2. Enzymatic Degradation in the Skin:33
Transferosomes may encounter enzymatic degradation by skin esterases, lipases, and proteases, which can compromise vesicle integrity or degrade the encapsulated drug before it reaches the target site. This is particularly relevant for peptide-based drugs or lipophilic carriers susceptible to enzymatic breakdown. The formulation must therefore consider enzyme inhibitors or protective surface coatings to prevent premature degradation.
3. Interaction with Skin Microbiome:34
Emerging studies suggest that commensal skin microbiota can affect the bioavailability and performance of topical vesicular systems. Certain bacteria can secrete surfactants, enzymes, or acids that interact with transferosomes, altering their permeability, stability, or degradation rate. A well-balanced microbiome may support drug diffusion, while dysbiosis (microbial imbalance) might compromise delivery.
4. Vesicle Elasticity and Membrane Flexibility:35
The elasticity or deformability of transferosomes is a critical pharmacotechnical factor that determines their ability to pass through narrow intercellular spaces in the skin. The type and concentration of edge activators (e.g., Tween 80, sodium cholate) directly influence this property. A higher deformability index correlates with improved skin penetration, especially in intact skin models.
5. Drug Physicochemical Properties:36
The solubility, molecular weight, charge, and partition coefficient of the drug significantly impact its encapsulation efficiency and release profile from transferosomes. Amphiphilic and moderately lipophilic drugs show better partitioning into lipid bilayers. Moreover, hydrophilic drugs may require optimization of hydration conditions and vesicle core volume to enhance loading.
6. Surface Charge (Zeta Potential) and Vesicle Stability:37
Zeta potential is a key indicator of colloidal stability. Transferosomes with moderately negative zeta potential (typically −20 to −40 mV) are more stable due to electrostatic repulsion, preventing aggregation over time. Zeta potential also influences skin interaction; slightly negative or neutral vesicles show improved adhesion and fusion with the skin.
7. Entrapment Efficiency and Drug Release Kinetics:38
Pharmacotechnical factors like the lipid-to-drug ratio, hydration time, and edge activator selection impact entrapment efficiency (EE). Higher EE ensures prolonged drug retention and sustained release. Transferosomes may follow Higuchi, Korsmeyer–Peppas, or zero-order kinetics, depending on formulation components and the nature of the drug.
8. Hydration Medium and pH Conditions:39
The pH and ionic strength of the hydration medium used during transferosome preparation directly affect vesicle formation, drug solubilization, and stability. Using buffer systems (e.g., citrate buffer, PBS) at physiological or slightly acidic pH levels enhances lipid bilayer flexibility and improves drug encapsulation—especially for pH-sensitive drugs.
6. Characterization of Transferosomes:
Characterization of transferosomes encompasses a suite of physicochemical and functional assays essential to ensuring their stability, efficacy, and transdermal performance.
1. Vesicle Size, Morphology, and Distribution:19
Dynamic Light Scattering (DLS) and Transmission Electron Microscopy (TEM) are routinely employed to determine average diameter, polydispersity index (PDI), and vesicle morphology. Ideal transferosomes typically range from 50–300 nm with PDI below 0.3 to ensure uniformity and reproducibility Photographing via TEM confirms unilamellar, spherical or slightly elongated vesicles, reflecting the elasticity induced by edge activators.
2. Entrapment Efficiency and Drug Content:19
Drug loading is quantified by separating free drug via centrifugation or dialysis and lysing the vesicles for spectrophotometric or HPLC measurement. Entrapment efficiencies often exceed 80 %, depending on lipid-to-drug ratios and surfactant type.
3. Zeta Potential and Surface Charge:40
Zeta potential analysis reveals colloidal stability; values around –20 to –40 mV generally indicates strong repulsion and long-term formulation stability. The presence of charged edge activators contributes to these potentials and affects interaction with the stratum corneum
4. Deformability or Permeability Index:41
A unique character of transferosomes is their ability to squeeze through pores much smaller than their diameter. Permeability indexes are assessed by forcing vesicles through microporous membranes (e.g., 50–400 nm filters), measuring size change and vesicle recovery. High deformability correlates with improved transdermal flux.
5. In Vitro Drug Release and Skin Permeation:19, 42
Franz diffusion cell studies using synthetic membranes or ex vivo skin (e.g. goat skin) quantify release profiles over hours and transdermal penetration. Transferosomes frequently exhibit controlled release and significantly higher cumulative permeation versus non-deformable vesicles.
6. Physical Stability and Occlusion Effects:19
Stability is evaluated via storage under different temperatures (e.g. 4°C, 25°C, 37°C) and periodic measuring of vesicle size, zeta potential, and entrapment efficiency. Occlusion studies assess whether vesicle hydration enhances penetration over time.
7. Spectroscopic and Thermal Analyses (Novel Additions)43
Recent work through 2025 includes FTIR, DSC, and XRD to assess lipid–drug interactions, crystallinity, and thermal stability, especially in drug-loaded transferosomes such as metformin-loaded formulations. These confirm successful incorporation and phase behavior essential for controlled release and structural integrity.
8. Specialized Application Case:44
Ocular Delivery tonabersat‑loaded ocular transferosomes, characterizing particle size (~120 nm), PDI (0.2), zeta potential (−25 mV), entrapment efficiency (~87 %), in vitro release, and ex vivo corneal permeation—demonstrating excellent ocular tolerance and sustained delivery.
7. APPLICATIONS OF TRANSFEROSOMES:
Transferosomes have demonstrated versatile therapeutic potential owing to their deformable and ultra-flexible structure, enabling enhanced skin penetration and targeted delivery of bioactive compounds. Their capacity to traverse intact stratum corneum makes them ideal carriers for transdermal and dermal drug delivery.
1. Skin Cancer Therapy:45
A prominent application of transferosomes lies in skin cancer treatment.the clinical potential of transferosome-based systems in delivering chemotherapeutic agents directly to tumor sites in skin cancer. Their study demonstrated improved localization, enhanced drug penetration, and reduced systemic toxicity, making them a promising approach for melanoma and squamous cell carcinoma.
2. Antiproliferative and Antiangiogenic Therapy: 46
Transferosomes have also been explored for their role in enhancing the bioavailability of phytochemicals like apigenin, a natural flavone with notable anticancer properties. in vitro and in vivo evaluations showing that apigenin-loaded vesicles exhibited superior antiproliferative and antiangiogenic activity against human melanoma cell lines, underlining the role of such vesicular carriers in oncologic nanotherapy.
3. Dermatological Disease Models: 47
The application of transferosomes has expanded into advanced dermatological models. three-dimensional (3D) in vitro and in vivo tools to study cutaneous squamous cell carcinoma, demonstrating the benefits of lipid-based vesicles in mimicking the tumor microenvironment and delivering drugs more effectively in experimental models.
4. Psoriasis and Inflammatory Skin Disorders:48
Recent studies have incorporated anti-inflammatory drugs within transferosomal carriers for treating chronic inflammatory conditions like psoriasis. These vesicles enable deeper penetration of corticosteroids or NSAIDs while minimizing side effects and systemic exposure.
5. Cosmeceutical Applications:49
Transferosomes are increasingly used in cosmetic formulations for anti-aging, skin hydration, and delivery of vitamins (e.g., vitamin C, retinol). Their ability to permeate deeper skin layers enables sustained release and improved skin rejuvenation outcomes.
6. Wound Healing:50
Transferosomes have been investigated for delivering growth factors and antimicrobial agents to promote wound healing. Their deformability allows them to reach deeper dermal layers, enhancing tissue regeneration and reducing microbial colonization.
7.1. Applications Based on Possible Formulations:
1. Transdermal Analgesic Delivery (e.g., Diclofenac, Lidocaine):51
These formulations offer sustained pain relief for arthritis, sciatica, and sports injuries by bypassing hepatic first-pass metabolism and delivering drugs directly to inflamed tissues. The deformable nature of vesicles improves skin penetration, allowing localized and systemic effects without gastrointestinal irritation.
2. Antifungal Drug Delivery (e.g., Fluconazole, Itraconazole):52
Transferosomal delivery enhances skin and nail bed penetration in conditions such as onychomycosis and cutaneous candidiasis, improving drug accumulation in infected tissues and minimizing systemic side effects associated with oral antifungals.
3. Hormone Replacement Therapy (e.g., Testosterone, Estrogen):53
Used for treating androgen deficiency, menopausal symptoms, and osteoporosis, transferosome-based hormone formulations provide controlled release and stable plasma levels, avoiding fluctuations seen in oral or injectable routes.
4. Anti-Aging and Cosmetic Applications (e.g., Coenzyme Q10, Retinol):54
These formulations help reduce wrinkle depth, improve skin elasticity, and enhance collagen synthesis by facilitating deep dermal delivery of actives that normally exhibit poor skin penetration.
5. Delivery of Anticancer Agents (e.g., 5-Fluorouracil, Curcumin):55
These systems enable localized treatment of cutaneous tumors, such as melanoma or squamous cell carcinoma, enhancing intradermal delivery, minimizing systemic toxicity, and improving patient compliance.
8. CONCLUSION:
Transfersomes have emerged as a cutting-edge innovation in transdermal and topical drug delivery systems. Their ultra-flexible lipid bilayer structure, empowered by edge activators, allows them to penetrate deep into the skin without causing damage, facilitating targeted and sustained drug release. These carriers offer remarkable advantages such as enhanced bioavailability, reduced systemic toxicity, and improved patient compliance, particularly in chronic and dermatological therapies. While limitations like formulation complexity, stability issues, and limited clinical translation persist, ongoing research and technological advancements continue to address these hurdles. The wide range of applications—from skin cancer management and anti-inflammatory therapies to cosmetic and wound healing uses—reflects their versatility and potential. As pharmaceutical science progresses, transfersomes are poised to play a pivotal role in the development of non-invasive, effective, and patient-centric drug delivery solutions.
9. REFERENCES:
1. Gupta R, Kumar A. Transfersomes: the ultra-deformable carrier system for non-invasive delivery of drug. Current Drug Delivery. 2021 May 1; 18(4): 408-20. https://doi.org/10.2174/1567201817666200804105416
2. Singh A, Fatima Z, Srivastava D. A Comprehensive Review on Polyphenols based Nanovesicular System for Topical Delivery. Current Drug Delivery. 2025 Mar; 22(2): 123-39. https://doi.org/10.2174/0115672018265118231213094410
3. Simrah, Hafeez A, Usmani SA, Izhar MP. Transfersome, an ultra-deformable lipid-based drug nanocarrier: an updated review with therapeutic applications. Naunyn-Schmiedeberg's Archives of Pharmacology. 2024 Feb; 397(2): 639-73. https://doi.org/10.1007/s00210-023-02670-8
4. Manchanda D, Makhija M, Pandey P, Sharma M. Transfersomes: Recent advances, mechanisms, exhaustive applications, clinical trials, and patents. Current Drug Delivery. 2025 Mar; 22(2): 215-30. https://doi.org/10.2174/0115672018295038240209055444
5. Ren, J., Liu, T., Bi, B., Sohail, S., and Din, F. U. Evaluation of tacrolimus-loaded nano-transfersomes for skin-targeted dermatitis therapy. Journal of Pharmaceutical Sciences. 2024; 113(2): 471–485. https://doi.org/10.1016/j.xphs.2023.10.033
6. Khalil, R., Mirza, R., Shah, K. U., Khan, A. U., Ismail, I., Shah, S. U., et al. Intranasal transfersomal based in situ gel for augmenting methylphenidate bioavailability and brain delivery. Journal of Drug Delivery Science and Technology. 2024; 101: 106125. https://doi.org/10.1016/j.jddst.2024.106125
7. Rafique, M., Ali, Z., Sohail, S., Zahid, F., Khan, M. I., Din, F. U., et al. Dexibuprofen loaded nano transfersomal gel with enhanced performance for arthritis treatment. Journal of Drug Delivery Science and Technology. 2024; 98: 105928. https://doi.org/10.1016/j.jddst.2024.105928
8. Hussain W, Ahmed N, Khan D, Ullah N, Hadi F, Mumtaz A, et al. Transdermal transfersomal hydrogel: A breakthrough in carbamazepine delivery for effective epilepsy management. J Drug Deliv Sci Technol. 2025; 107: 106827. https://doi.org/10.1016/j.jddst.2025.106827.
9. Sun, Y., Zhang, Y., Liu, X., Tingting, Y., Shen, L., and Ye, D. High minoxidil-loaded transfersomal gel for alopecia treatment. Journal of Drug Delivery Science and Technology. 2023; 84: 104458. https://doi.org/10.1016/j.jddst.2023.104458
10. Afzal I, Zeb A, Mazhar D, Khan JZ, Altaf S, Ain Q, et al. Folic acid grafted tofacitinib loaded targeted transfersomes for transdermal delivery against breast cancer. J Drug Deliv Sci Technol. 2025; 106: 106711. https://doi.org/10.1016/j.jddst.2025.106711.
11. Miatmoko A, Dewangga SS, Handoko KK, Legowo D, Purwantari KE, Susanto J, et al. Transfersomal serum loading amniotic mesenchymal stem cells metabolite products with hyaluronic acid addition for skin regeneration in UV aging-induced mice. Int J Pharm. 2024; 667(B): 124950. https://doi.org/10.1016/j.ijpharm.2024.124950.
12. Khan AU, Jamshaid H, Din FU, Zeb A, Khan GM. Designing, Optimization and Characterization of Trifluralin Transfersomal Gel to Passively Target Cutaneous Leishmaniasis. J Pharm Sci. 2022; 111(6): 1798-1811. https://doi.org/10.1016/j.xphs.2022.01.010.
13. Nayeem U, Garg A, Das AK, Shree N, Yasmeen, Sultana Y, et al. Development and evaluation of the novel chitosan-based 1% clindamycin and 2.5% benzoyl peroxide transferosomal gel for topical acne treatment. J Drug Deliv Sci Technol. 2023; 89: 105002. https://doi.org/10.1016/j.jddst.2023.105002.
14. Rahman M, Indabawa AH, Alam K, Beg S, Sahoo A. Chapter 15 - Transferosomes drug delivery in topical infectious disorders. In: Beg S, Shukla R, Handa M, Rahman M, Dhir A, editors. Nanostructured Drug Delivery Systems in Infectious Disease Treatment. Academic Press; 2024. p. 351-367. https://doi.org/10.1016/B978-0-443-13337-4.00011-2.
15. Opatha, S. A. T., Chutoprapat, R., Khankaew, P., Titapiwatanakun, V., Ruksiriwanich, W., and Boonpisuttinant, K. (2024). Asiatic acid-entrapped transfersomes for hypertrophic scars: In vitro and clinical evaluation. International Journal of Pharmaceutics, 651, 123738. https://doi.org/10.1016/j.ijpharm.2023.123738
16. Mazhar, D., Haq, N. U., Zeeshan, M., Ain, Q., Ali, H., Khan, S., et al. Pharmacokinetic assessment of metformin HCl loaded transfersomes with permeation enhancers. Journal of Drug Delivery Science and Technology. 2023; 84: 104448. https://doi.org/10.1016/j.jddst.2023.104448
17. Prashanthini, V. P., Sivaraman, S., Kathirvelu, P., Shanmugasundaram, J., Subramanian, V., and Ramesh, S. S. Transfersomal gel for transdermal insulin delivery: Formulation and permeation study. Intelligent Pharmacology. 2023; 1(4): 212–216. https://doi.org/10.1016/j.ipha.2023.07.001
18. Hamed R, Alkilani AZ, Al-Adhami Y, Musleh B, Aburayya R. Advances in transdermal delivery systems for Antifungals: Current approaches and future perspectives. Microb Pathog. 2025; 206: 107776. https://doi.org/10.1016/j.micpath.2025.107776.
19. Fatima, A., Suresh Babu, M., et al. Characterization of transferosomes: Entrapment efficiency, vesicle size, morphology, zeta potential, and in vitro skin permeation. IJPPR Human. 2023; 28(2): 27–37.
20. Ahmad, A., Sharma, S., and Khan, S. Transfersomes: A novel approach for transdermal drug delivery. International Journal of Pharmaceutical Sciences and Research. 2020; 11(5): 1007–1013.
21. Gupta, A., and Yadav, K. S. Transfersomes: A novel vesicular carrier for enhanced transdermal drug delivery. Journal of Drug Delivery Science and Technology. 2021; 61: 102267. https://doi.org/10.1016/j.jddst.2021.102267
22. Tiwari, A., Verma, R. K., and Rai, G. Formulation and evaluation of transfersomal gel for transdermal delivery of sertraline. Journal of Drug Delivery and Therapeutics. 2020; 10(6): 125–131.
23. Agarwal, R., and Mehta, T. Recent advances in vesicular systems for effective transdermal drug delivery. Pharmaceutical Nanotechnology. 2021; 9(3): 162–174.
24. Pandey, V., and Singh, M. Lipid-based nanocarriers for skin delivery: Advances and challenges. Pharmaceutical Nanotechnology. 2023; 11(2): 96–112.
25. Mahto, R. K., and Sharma, A. Supercritical fluid technology in lipid vesicle preparation: A futuristic approach. Journal of Translational Medicine. 2024; 22(1): 78. https://doi.org/10.1186/s12967-024-05160-4
26. Gadag S, Narayan R, Sabhahit JN, Hari G, Nayak Y, Pai KS, Garg S, Nayak UY. Transpapillary iontophoretic delivery of resveratrol loaded transfersomes for localized delivery to breast cancer. Biomaterials Advances. 2022 Sep 1; 140: 213085. https://doi.org/10.1016/j.bioadv.2022.213085
27. Opatha SA, Titapiwatanakun V, Boonpisutiinant K, Chutoprapat R. Preparation, characterization and permeation study of topical gel loaded with transfersomes containing asiatic acid. Molecules. 2022 Jul 29; 27(15): 4865. https://doi.org/10.3390/molecules27154865
28. Abdallah, M. H., Abu Lila, A. S., Shawky, S. M., Almansour, K., Alshammari, F., Khafagy, E.-S. and Younis, M. A. Experimental design and optimization of nano-transfersomal gel to enhance the hypoglycemic activity of silymarin. Polymers. 2022; 14(3): 508. https://doi.org/10.3390/polym14030508
29. Pertiwi, R. D., Firti, S. A., Putri, D. A., and Hurit, H. E. Optimization of formula using D-Optimal design method and stability testing of ascorbic acid transferosomes gel. Tropical Journal of Natural Product Research. 2025; 9(3): 912–920. https://doi.org/10.26538/tjnpr/v9i3.23
30. Saritha, D., and Janapareddi, K. Bioavailability enhancement of nebivolol hydrochloride loaded transferosomes via transdermal route: Pharmacokinetic and pharmacodynamic evaluation in rats. Journal of Young Pharmacists. 2024; 16(4): 772–780. https://doi.org/10.5530/jyp.2024.16.148
31. Lavani, F., Haranath, C., Yasaswini, S., Sai, R. N., and Satish, T. Exploring Transferosomes: A comprehensive review of novel strategies and applications in drug delivery. Journal of Young Pharmacists. 2024; 16(3): 410–415. https://doi.org/10.5530/jyp.2024.16.83
32. Chauhan, A., Jain, A., and Bansal, P. Effect of hydration medium and pH on transferosomal characteristics and drug release. Pharmaceutical Development and Technology. 2023; 28(2): 210–219. https://doi.org/10.1080/10837450.2023.2162140
33. Patel, D., Sharma, K., and Deshmukh, R. Enhancing dermal penetration using transferosomes: Role of penetration enhancers and co-surfactants. International Journal of Pharmaceutics. 2025; 635: 122989. https://doi.org/10.1016/j.ijpharm.2025.122989
34. Sharma, S., and Rathore, S. Role of skin microstructure in influencing nanocarrier-based drug delivery systems. European Journal of Pharmaceutics and Biopharmaceutics. 2023; 189: 123-132. https://doi.org/10.1016/j.ejpb.2023.08.004
35. Kumar, R., and Taneja, S. Strategies to overcome enzymatic degradation of lipid vesicles in topical drug delivery. Current Pharmaceutical Design. 2024; 30(1): 45–54. https://doi.org/10.2174/1381612829666230919160348
36. Mehta, D., and Bose, A. Nanocarriers and the skin microbiome: A double-edged sword in dermal drug delivery. Advanced Drug Delivery Reviews. 2025; 207: 114586. https://doi.org/10.1016/j.addr.2024.114586
37. Rautray, T. K., and Das, L. Tailoring vesicle elasticity for improved transdermal drug delivery: Advances in transferosomal systems. Pharmaceutical Research. 2024; 41(2): 123–135. https://doi.org/10.1007/s11095-024-03581-9
38. Singh, A., and Kaur, P. Influence of drug physicochemical properties on entrapment and diffusion in lipid-based vesicular systems. Journal of Drug Delivery Science and Technology. 2023; 8: 104231. https://doi.org/10.1016/j.jddst.2023.104231
39. Haque, A., and Joshi, H. Role of zeta potential in determining the fate of lipid vesicles in dermal applications. International Journal of Pharmaceutics. 2023; 634: 122711. https://doi.org/10.1016/j.ijpharm.2023.122711
40. Banerjee, R., and Khatun, Z. Evaluation of release kinetics in transferosome-based dermal drug carriers. Drug Development and Industrial Pharmacy. 2024; 50(3): 287–297. https://doi.org/10.1080/03639045.2024.1992047
41. Bhatia, V., and Jaiswal, P. Influence of hydration media and pH on formulation behavior of ultra-deformable vesicles. Colloids and Surfaces B: Biointerfaces. 2023; 225: 113194. https://doi.org/10.1016/j.colsurfb.2023.113194
42. Chauhan, S., Barman, M., and Singh, M. Recent advances and prospects of transferosomes for transdermal delivery. Trends in Drug Delivery. 2024; 11(3): 1–22.
43. Rajendran, A., Elumalai, V., Balasubramaniyam, S., and Elumalai, K. Transferosome formulations as innovative carriers for transdermal drug delivery: Composition, properties, and therapeutic applications. Biomedical Materials and Devices. 2025 https://doi.org/10.1007/s44174-024-00269-y
44. Bhujbal, S., Rupenthal, I. D., and Agarwal, P. Formulation and characterization of transfersomes for ocular delivery of tonabersat. Pharmaceutical Development and Technology. 2025; 1: 4. https://doi.org/10.1080/10837450.2025.2501991
45. Mohaddish, M., Jilani, M., Rehman, U., Ramaiah, R., Hani, U., and Gupta, G. et al. Recent advances in the clinical application of transferosomes for skin cancer management. Colloids and Surfaces B: Biointerfaces. 202; 254: 114877. https://doi.org/10.1016/j.colsurfb.2025.114877
46. Ghițu, A., Pavel, I. Z., Avram, S., Kis, B., Minda, D., Dehelean, C. A., Buda, V., Folescu, R., and Danciu, C. An in vitro-in vivo evaluation of the antiproliferative and antiangiogenic effect of flavone apigenin against SK‐MEL‐24 human melanoma cell line. Analytical Cellular Pathology. 2021; 2021(1): 5552664. https://doi.org/10.1155/2021/5552664
47. Quadri, M., Marconi, A., Sandhu, S. K., Kiss, A., Efimova, T., and Palazzo, E. Investigating cutaneous squamous cell carcinoma in vitro and in vivo: novel 3D tools and animal models. Frontiers in Medicine. 2022; 9: 875517. https://doi.org/10.3389/fmed.2022.875517
48. Albash, R., Alomrani, A., Alqahtani, A., Alhowail, A. H., and Imam, S. S. (). Transferosomes for topical delivery of anti-inflammatory agents in psoriasis: formulation, characterization, and in vivo evaluation. Pharmaceutical Development and Technology. 2023; 28(1): 88–96. https://doi.org/10.1080/10837450.2022.2154078
49. Ravikumar, N., Suryawanshi, M., Kulkarni, R., and Rane, B. (). Cosmeceutical potential of transferosomes in dermal delivery of anti-aging agents: An overview. Journal of Cosmetic Dermatology. 2022; 21(5): 2201–2212. https://doi.org/10.1111/jocd.14667
50. Zhao, Y., Li, S., Wang, X., Chen, Y., and Huang, Y. Transferosomal delivery of antimicrobial peptides enhances wound healing in infected skin. International Journal of Pharmaceutics. 2024; 634: 122884. https://doi.org/10.1016/j.ijpharm.2024.122884
51. Kaur, G., and Narang, R. K. Transferosomal gel of diclofenac for enhanced transdermal delivery: Formulation and in vivo evaluation. European Journal of Pharmaceutical Sciences. 2023; 184: 106481. https://doi.org/10.1016/j.ejps.2023.106481
52. Patel, S., and Shah, K. Design and optimization of fluconazole-loaded transferosomes for effective antifungal therapy. Journal of Drug Delivery Science and Technology. 2024; 86: 104721. https://doi.org/10.1016/j.jddst.2024.104721
53. Ahmed, R., and Bhatt, D. Transdermal delivery of testosterone via transferosomes: A clinical approach to sustained hormone therapy. Pharmaceutical Development and Technology. 2025; 30(2): 144–155. https://doi.org/10.1080/10837450.2025.1992341
54. Malik, A., and Joshi, A. Transferosome-based cosmeceuticals for dermal delivery of anti-aging agents: A mechanistic insight. Journal of Cosmetic Dermatology. 2023; 22(8): 2179–2188. https://doi.org/10.1111/jocd.15842
55. Saxena, P., and Verma, N. Curcumin-loaded transferosomes for topical treatment of skin cancer: Formulation development and therapeutic efficacy. Colloids and Surfaces B: Biointerfaces. 2025; 225: 113284. https://doi.org/10.1016/j.colsurfb.2025.113284
|
Received on 05.08.2025 Revised on 28.08.2025 Accepted on 16.09.2025 Published on 08.10.2025 Available online from October 17, 2025 Asian J. Pharm. Tech. 2025; 15(4):395-404. DOI: 10.52711/2231-5713.2025.00057 ©Asian Pharma Press All Right Reserved
|
|
|
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License. |
|